| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sang-Yoon Lee, Yearn Seong Choe, Yu Ri Kim, Jin-Young Paik, Byoung Wook Choi, Sang Eun Kim, Kyung-Han Lee, Yong Choi, Byung-Tae Ki. Synthesis and evaluation of 5,7-dihydro-3-[2-[1-(4-[18F]-fluorobenzyl)-4-piperidinyl]ethyl]-6H-pyrrolo[3,2-f]-1,2-benzisoxazol-6-one for in vivo mapping of acetylcholinesterase. Nuclear medicine communications. vol 25. issue 6. 2004-12-20. PMID:15167519. |
acetylcholinesterase (ache) is an important cholinergic marker for the diagnosis of alzheimer's disease (ad). |
2004-12-20 |
2023-08-12 |
Not clear |
| Roger M Lane, Miia Kivipelto, Nigel H Grei. Acetylcholinesterase and its inhibition in Alzheimer disease. Clinical neuropharmacology. vol 27. issue 3. 2004-09-27. PMID:15190239. |
therefore, the use of ache inhibitors to treat symptoms caused by cholinergic imbalances in alzheimer disease (ad) represented a rational approach. |
2004-09-27 |
2023-08-12 |
Not clear |
| Neal E Slatkin, Michelle Rhine. Treatment of opiate-related sedation: utility of the cholinesterase inhibitors. The journal of supportive oncology. vol 1. issue 1. 2004-09-21. PMID:15352644. |
preliminary studies with donepezil, a centrally acting acetylcholinesterase (ache) inhibitor approved for use in alzheimer's disease, have suggested at least short-term benefit in treating opiate-related sedation. |
2004-09-21 |
2023-08-12 |
Not clear |
| Francesco Gambi, Marcella Reale, Carla Iarlori, Anatolia Salone, Lucia Toma, Carlo Paladini, Giovanna De Luca, Claudio Feliciani, Mirella Salvatore, Rosa M Salerno, Theoharis C Theoharides, Pio Conti, Michael Exton, Domenico Gamb. Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells. Journal of clinical psychopharmacology. vol 24. issue 3. 2004-09-07. PMID:15118486. |
alzheimer patients treated with an ache inhibitor show higher il-4 and lower il-1 beta levels and expression in peripheral blood mononuclear cells. |
2004-09-07 |
2023-08-12 |
human |
| Maria Laura Bolognesi, Andrea Cavalli, Vincenza Andrisano, Manuela Bartolini, Rita Banzi, Alessandra Antonello, Michela Rosini, Carlo Melchiorr. Design, synthesis and biological evaluation of ambenonium derivatives as AChE inhibitors. Farmaco (Societa chimica italiana : 1989). vol 58. issue 9. 2004-08-24. PMID:13679187. |
ambenonium (1), an old ache inhibitor, is endowed with an outstanding affinity and a peculiar mechanism of action that, taken together, make it a very promising pharmacological tool for the treatment of alzheimer's disease (ad). |
2004-08-24 |
2023-08-12 |
human |
| Sultan Darvesh, Rakesh C Arora, Earl Martin, David Magee, David A Hopkins, J Andrew Armou. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons. Experimental neurology. vol 188. issue 2. 2004-08-10. PMID:15246845. |
cholinesterase inhibitors used to treat the symptoms of alzheimer's disease (ad) inhibit both acetylcholinesterase (ache) and butyrylcholinesterase (buche), albeit to different degrees. |
2004-08-10 |
2023-08-12 |
Not clear |
| Yuhao Ren, Peter J Houghton, Robert C Hider, Melanie-Jayne R Howe. Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. Planta medica. vol 70. issue 3. 2004-08-09. PMID:15114495. |
acetylcholinesterase (ache, ec 3.1.1.7) inhibitors are the only registered drugs used to treat alzheimer's disease (ad). |
2004-08-09 |
2023-08-12 |
Not clear |
| T Day, S A Greenfiel. Bioactivity of a peptide derived from acetylcholinesterase in hippocampal organotypic cultures. Experimental brain research. vol 155. issue 4. 2004-07-20. PMID:14685807. |
in conclusion, the bioactivity associated with the ache-peptide sequence may account for the non-cholinergic actions of ache, whilst its neurotrophic-apoptotic-necrotic spectrum of action may be involved in the aetiology of neurodegenerative disorders such as alzheimer's disease. |
2004-07-20 |
2023-08-12 |
rat |
| Yasuyuki Abe, Atsushi Aoyagi, Takao Hara, Kazumi Abe, Reina Yamazaki, Yoshihiro Kumagae, Shunji Naruto, Kazuo Koyama, Shinji Marumoto, Keiko Tago, Narihiro Toda, Kazuko Takami, Naho Yamada, Mayuko Ori, Hiroshi Kogen, Tsugio Kanek. Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease. Journal of pharmacological sciences. vol 93. issue 1. 2004-07-09. PMID:14501158. |
these results suggest that both cholinergic and serotonergic systems are involved in maintaining brain arousal and that a dual inhibitor of ache and sert may be useful for the treatment of cognitive disorders associated with reduced brain activity such as in alzheimer's disease. |
2004-07-09 |
2023-08-12 |
mouse |
| Ariel E Reyes, Marcelo A Chacón, Margarita C Dinamarca, Waldo Cerpa, Carlos Morgan, Nibaldo C Inestros. Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat beta-amyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. The American journal of pathology. vol 164. issue 6. 2004-07-08. PMID:15161650. |
our studies are consistent with the notion that abeta-ache complexes are more toxic than abeta fibrils and that ache triggered some of the neurodegenerative changes observed in alzheimer's disease brains. |
2004-07-08 |
2023-08-12 |
human |
| Kornkanok Ingkaninan, Prapapan Temkitthawon, Kanchanaporn Chuenchom, Thitaree Yuyaem, Warawit Thongno. Screening for acetylcholinesterase inhibitory activity in plants used in Thai traditional rejuvenating and neurotonic remedies. Journal of ethnopharmacology. vol 89. issue 2-3. 2004-06-29. PMID:14611889. |
acetylcholinesterase (ache) inhibitor has been used as a drug for the symptomatic treatment of alzheimer's disease. |
2004-06-29 |
2023-08-12 |
Not clear |
| Hitoshi Shinotoh, Kiyoshi Fukushi, Shin-ichiro Nagatsuka, Toshiaki Iri. Acetylcholinesterase imaging: its use in therapy evaluation and drug design. Current pharmaceutical design. vol 10. issue 13. 2004-06-21. PMID:15134572. |
both [(11)c]mp4a- and [(11)c]mp4p-pet have demonstrated not only the reduction of ache activity in the cerebral cortex of patients with alzheimer's disease (ad) but also the inhibitory effects of donepezil and rivastigmine on ache activity in the brain of ad patients. |
2004-06-21 |
2023-08-12 |
human |
| Z Rakoncza. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta biologica Hungarica. vol 54. issue 2. 2004-06-02. PMID:14535624. |
additionally, the ic50 values of different molecular forms of ache (monomeric, g1, and tetrameric, g4) were determined in the cerebral cortex in both normal and alzheimer's human brains. |
2004-06-02 |
2023-08-12 |
human |
| Z Rakoncza. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain. Acta biologica Hungarica. vol 54. issue 2. 2004-06-02. PMID:14535624. |
interestingly, the ache molecular forms in alzheimer samples were more sensitive to some of the inhibitors as compared with the normal samples. |
2004-06-02 |
2023-08-12 |
human |
| Narihiro Toda, Keiko Tago, Shinji Marumoto, Kazuko Takami, Mayuko Ori, Naho Yamada, Kazuo Koyama, Shunji Naruto, Kazumi Abe, Reina Yamazaki, Takao Hara, Atsushi Aoyagi, Yasuyuki Abe, Tsugio Kaneko, Hiroshi Koge. A conformational restriction approach to the development of dual inhibitors of acetylcholinesterase and serotonin transporter as potential agents for Alzheimer's disease. Bioorganic & medicinal chemistry. vol 11. issue 20. 2004-06-01. PMID:13129577. |
alzheimer's disease (ad) has been treated with acetylcholinesterase (ache) inhibitors such as donepezil. |
2004-06-01 |
2023-08-12 |
Not clear |
| Ho Jin Heo, Mi-Jeong Kim, Jung-Min Lee, Soo Jung Choi, Hong-Yon Cho, Bumshik Hong, Hye-Kyung Kim, Eunki Kim, Dong-Hoon Shi. Naringenin from Citrus junos has an inhibitory effect on acetylcholinesterase and a mitigating effect on amnesia. Dementia and geriatric cognitive disorders. vol 17. issue 3. 2004-05-03. PMID:14739537. |
this study was performed to identify safe and more effective acetylcholinesterase (ache) inhibitors in the treatment of alzheimer's disease. |
2004-05-03 |
2023-08-12 |
mouse |
| Si-lang Zhou, Jun-pao Chen, Xiao-wen Tu, Dong-lin Cao, Dai-jun Yua. [Effects of basic fibroblast growth factor on rat models of Alzheimer disease]. Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA. vol 23. issue 6. 2004-04-16. PMID:12810391. |
to study the effects of basic fibroblast growth factor (bfgf) on the praxiology and cerebral acetylcholinesterase (ache) fiber density of kainic acid-lesioned rat models of alzheimer disease (ad). |
2004-04-16 |
2023-08-12 |
rat |
| Esperanza Arias, Eva Alés, Nelson H Gabilan, María F Cano-Abad, Mercedes Villarroya, Antonio G García, Manuela G Lópe. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors. Neuropharmacology. vol 46. issue 1. 2004-04-05. PMID:14654102. |
galantamine is currently used to treat alzheimer's disease patients; it behaves as a mild blocker of acetylcholinesterase (ache) and has an allosteric modulating action on nicotinic acetylcholine receptors (nachrs). |
2004-04-05 |
2023-08-12 |
human |
| T Darreh-Shori, E Hellström-Lindahl, C Flores-Flores, Z Z Guan, H Soreq, A Nordber. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. Journal of neurochemistry. vol 88. issue 5. 2004-03-30. PMID:15009666. |
both ache-r and ache-s splice variants as well as several heavier ache complexes were detected in brain homogenates from the parietal cortex of patients with or without alzheimer's disease (ad) as well as the cerebrospinal fluid (csf) of ad patients, compatible with the assumption that csf aches might originate from cns neurons. |
2004-03-30 |
2023-08-12 |
Not clear |
| L R Fodero, S S Mok, D Losic, L L Martin, M I Aguilar, C J Barrow, B G Livett, D H Smal. Alpha7-nicotinic acetylcholine receptors mediate an Abeta(1-42)-induced increase in the level of acetylcholinesterase in primary cortical neurones. Journal of neurochemistry. vol 88. issue 5. 2004-03-30. PMID:15009674. |
although there is a loss of acetylcholinesterase (ache) from both cholinergic and non-cholinergic neurones in the brain of alzheimer patients, the level of ache is increased around amyloid plaques. |
2004-03-30 |
2023-08-12 |
mouse |